Fig. 6: Immune analysis with risk status. | npj Precision Oncology

Fig. 6: Immune analysis with risk status.

From: Molecular characterization and prognostic implications of KRAS mutations in pancreatic cancer patients: insights from multi-cohort analysis

Fig. 6

A–C Bar charts displaying the proportion of PD-L1 expression (TPS ≥ 1%) stratified by KRAS mutation status, TP53 mutation status, and risk status in SDFM cohort (n = 113). Statistical significance was evaluated using the Chi-square test, and p-values are indicated; D Correlation analysis between TMB and PD-L1 expression. Spearman’s correlation coefficient (R) and corresponding p-value are shown; E–H The expression levels of immune checkpoint genes (CD274, CTLA4, and PDCD1), ESTIMATE scores, TIMER immune infiltration scores, and QUANTISEQ scores between low-risk (blue) and high-risk (red) groups in TCGA cohort, “*”, “**”, and “***” indicate P < 0.05, P < 0.011, and P < 0.001, Wilcoxon rank-sum test. Exploratory analyses with FDR-adjusted p-values in Supplementary Table S11, see “Methods” for analysis definitions.

Back to article page